Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3488 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 5 6 7 ... 33 34 35  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
VectivBio–Forbion: investment, 202305 existent shareholder Forbion 2023-05-01
Clickmer Systems–APIS Assay Technologies: investment, 202204 acquisition of Clickmer Systems for single-digit €m by APIS Assay Technologies Ltd 2023-04-25
Forbion–SEVERAL: investment, 202304 final close of Forbion Growth Opportunities Fund II with addit €130m bringing total fund size to hard cap €600m 2023-04-19
Forbion–SEVERAL: investment, 202304 final close €750m of Forbion Ventures Fund VI 2023-04-19
Gilde Investment–SEVERAL: investment, 202304 announced new Gilde Healthcare Venture&Growth VI with €600m investor commitments 2023-04-19
Ariceum Therapeutics–Andera Partners: investment, 202304 financing round Series A extension totalling €22.75m incl new + co-lead investor Andera 2023-04-18
Ariceum Therapeutics–Bellevue: investment, 202304 financing round Series A extension totalling €22.75m incl existing + co-investor Pureos Bioventures 2023-04-18
Ariceum Therapeutics–Earlybird: investment, 202304 financing round Series A extension totalling €22.75m incl new + co-lead investor Earlybird VC 2023-04-18
Ariceum Therapeutics–SEVERAL: investment, 202304 financing round Series A extension €22.75m bringing total Series A to €47.75m 2023-04-18
Zetta Genomics–Apex Ventures: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Apex Ventures 2023-04-18
Zetta Genomics–SEVERAL: investment, 202304 2nd seed financing round £1.9m with led by Nina Capital 2023-04-18
Zetta Genomics–Univ Cambridge: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Cambridge Enterprise 2023-04-18
Bio-Techne–Lunaphore: spatial omics, 202304– collab strategic partnership integrating COMET system with RNAscope technology 2023-04-17
Complement Therapeutics–BioGeneration Ventures: investment, 202304 financing round Series A totalling €72m incl exising + co-investor BGV 2023-04-17
Complement Therapeutics–Cambridge Innovation Capital: investment, 202304 financing round Series A totalling €72m incl new + co-investor CIC 2023-04-17
Complement Therapeutics–Forbion: investment, 202304 financing round Series A totalling €72m incl exising + co-lead investor Forbion 2023-04-17
Complement Therapeutics–Gimv: investment, 202304 financing round Series A totalling €72m incl new + lead investor Gimv 2023-04-17
Complement Therapeutics–Hadean Ventures: investment, 202304 financing round Series A totalling €72m incl new + co-investor Hadean Ventures 2023-04-17
Complement Therapeutics–Panakès Partners: investment, 202304 financing round Series A totalling €72m incl new + co-investor Panakès Partners 2023-04-17
Complement Therapeutics–Seroba: investment, 202304 financing round Series A totalling €72m incl new + co-investor Seroba Life Sciences 2023-04-17
Complement Therapeutics–SEVERAL: investment, 202304 financing round Series A €72m led by new investor Gimv 2023-04-17
Syngenta–Ginkgo Bioworks: seed technology, 202304– collab research using protein engineering + uHTS technologies to design + develop new plant traits 2023-04-17
CellPhenomics–Kyan Therapeutics: drug development technology, 202304– collab combi Optim.AI technology with PD3D technology for drug development 2023-04-14
Alentis Therapeutics–Bellevue: investment, 202304 financing round Series C totalling $105m incl existing + co-investor BB Pureos Bioventures 2023-04-13
Alentis Therapeutics–France (govt): investment, 202304 financing round Series C totalling $105m incl existing + co-investor InnoBio 2 Fund 2023-04-13
Alentis Therapeutics–Jeito Capital: investment, 202304 financing round Series C totalling $105m incl existing + lead investor Jeito Capital 2023-04-13
Alentis Therapeutics–Novo Group: investment, 202304 financing round Series C totalling $105m incl new + co-lead investor Novo Holdings A/S 2023-04-13
Alentis Therapeutics–RA Capital: investment, 202304 financing round Series C totalling $105m incl new + co-lead investor RA Capital Management 2023-04-13
Alentis Therapeutics–Schroders: investment, 202304 financing round Series C totalling $105m incl existing + co-investor Schroders Capital 2023-04-13
Alentis Therapeutics–SEVERAL: investment, 202304 financing round Series C $105m led by Jeito Capital with Novo Holdings + RA Capital 2023-04-13
InflaRx–SEVERAL: investment, 202304 public offering $40m + $6m with 9.4m + 1.4m ordinary shares at $4.25/share 2023-04-11
Merck (US)–Proxygen: molecular glue degraders, 202304– strategic multi-year collab + license agreem upfront payment + €2.55b milestones plus royalties 2023-04-05
Proxygen–Vida Strategic Partners: public relations, 202304 service existent by Vida Strategic Partners 2023-04-05
AMSilk–Cargill: investment, 202304 financing round Series C extension totalling €24m incl existing + co-investor Cargill 2023-04-04
AMSilk–MIG Fonds: investment, 202304 financing round Series C extension totalling €24m incl existing + co-investor MIG Capital 2023-04-04
AMSilk–Novo Group: investment, 202304 financing round Series C extension totalling €24m incl existing + co-investor Novo Holdings 2023-04-04
AMSilk–Optimum Strategic Communications: public relations, 202304 service existent by Optimum 2023-04-04
AMSilk–SEVERAL: investment, 202304 financing round Series C extension €24m led by AT Newtec bringing total round to €54m 2023-04-04
AMSilk–Strüngmann Group: investment, 202304 financing round Series C extension totalling €24m incl existing + lead investor Athos (AT Newtec) 2023-04-04
Biocartis–APIS Assay Technologies: molecular diagnostics, 202304– collab developm + commerc APIS Breast Cancer Subtyping assay on Idylla platform 2023-04-04
Point Biopharma–Eckert & Ziegler: radiopharmaceuticals, 202304– supply of nca actinum-225 to Point Biopharma 2023-04-04
BioNTech–Duality Biologics: antibody-drug conjugates, 202304– license excl ww excl China for DB-1303 + DB-131 $170m upfront + >$1.5b milestones + roy 2023-04-03
InSphero–Carl Zeiss: investment, 202303 financing round totalling 8-digit incl lead investor Zeiss Ventures 2023-03-31
InSphero–SEVERAL: investment, 202303 financing round 8-digit led by Zeiss Ventures 2023-03-31
Polyplus-transfection–Sartorius: investment, 202303– acquisition €2.4b of Polyplus by SSB from Archimed + Warburg Pincus et al 2023-03-31
Deepc–Bertelsmann: investment, 202303 financing round Series A totalling €12m incl new + co-investor Bertelsmann Investments 2023-03-28
Deepc–SEVERAL: investment, 202303 financing round Series A €12m led by Sofinnova Partners 2023-03-28
Deepc–Sofinnova: investment, 202303 financing round Series A totalling €12m incl new + lead investor Sofinnova Partners 2023-03-28
Deepc–Winning Mindset Ventures: investment, 202303 financing round Series A totalling €12m incl existing + co-investor Winning Mindset Ventures 2023-03-28
Novartis–Bicycle Therapeutics: Bicycle technology, 202303– strategic collab $50m upfront + $1.7b milestones for targeted radiopharmaceuticals 2023-03-28
Thermosome–Akampion: public relations, 202303 service existent by Akampion 2023-03-28
Vertex–CRISPR Therapeutics: CRISPR technology, 202303– license non-excl $100m upfront + $230m milestones + royalties CRISPR/Cas9 for cell therapies 2023-03-27
Lunaphore–Norgine: credit, 202303– venture debt €10m from Norgine Ventures 2023-03-23
Lunaphore–SEVERAL: investment, 202303 financing round Series D first closing approx CHF30m led by EGSB 2023-03-23
Mbiomics–Bavaria (govt): investment, 202303 financing round Series A first closing totalling €13m incl co-investor Bayern Kapital 2023-03-23
Mbiomics–High-Tech Gründerfonds: investment, 202303 financing round Series A first closing totalling €13m incl co-investor HTGF 2023-03-23
Mbiomics–MIG Fonds: investment, 202303 financing round Series A first closing totalling €13m incl lead investor MIG Capital 2023-03-23
Mbiomics–OTHER: investment, 202303 financing round Series A first closing totalling €13m incl pool of private seed investors 2023-03-23
Mbiomics–SEVERAL: investment, 202303 financing round Series A first closing €13m led by MIG Capital 2023-03-23
Lilly–Roche: Alzheimer blood test, 202303– collab development of Elecsys Amyloid Plasma Panel for early detection of Alzeimer’s diseasse 2023-03-22
BioNTech–OncoC4: antibody cancer drug, 202303– license ww excl + co-developm incl $200m upfront of anti-CTLA-4 mAb ONC-392 2023-03-20
Aldena Therapeutics–Medicxi: investment, 202303 Aldena emerges with $30m investment from co-founder Medicxi 2023-03-16
Lino Biotech–Miltenyi Biotec: investment, 202303 acquisition €na of Lino Biotech by Miltenyi Biotec 2023-03-16
Seamless Therapeutics–Forbion: investment, 202303 seed financing round totalling €7.9m incl co-lead investor Forbion 2023-03-16
Seamless Therapeutics–SEVERAL: investment, 202303 seed financing round €7.9m led by Wellington Partners + Forbion 2023-03-16
Seamless Therapeutics–Trophic Communications: public relations, 202303 service existent by Trophic 2023-03-16
Seamless Therapeutics–Wellington Partners: investment, 202303 seed financing round totalling €7.9m incl co-lead investor Wellington Partners 2023-03-16
Turnstone Biologics–Scailyte: biomarker discovery, 202303– collab biomarker discovery for TIL therapy using ScaiVision platform 2023-03-16
Mediar Therapeutics–Novartis: investment, 202303c financing round Series A totalling $85m incl co-lead investor Novartis Venture Fund 2023-03-15
Mediar Therapeutics–SEVERAL: investment, 202303c financing round Series A $85m co-led by NVF + Sofinnova Partners 2023-03-15
Iktos–Debiopharm: investment, 202303 financing round Series A totalling €15.5m incl new + co-lead investor Debiopharm Innovation Fund 2023-03-09
Iktos–Merck (DE): investment, 202303 financing round Series A totalling €15.5m incl new + co-lead investor M Ventures 2023-03-09
Iktos–Omnes Capital: investment, 202303 financing round Series A totalling €15.5m incl co-investor Omnes Capital 2023-03-09
Iktos–SEVERAL: investment, 202303 financing round Series A €15.5m co-led by M Ventures + Debiopharm Innovation Fund 2023-03-09
Cellbox Solutions–SEVERAL: investment, 202303 financing round Series A1 €6.5m led by CK Ventures 2023-03-07
Noema Pharma–SEVERAL: investment, 202303 financing round Series B CHF103m ($12m) co-led by Forbion + Jeito Capital 2023-03-07
Calibre Scientific–Eppendorf: micromanipulation products, 202303 acquisition of micromanipulation product portfolio of Eppendorf by Calibre Scientific 2023-03-06
Confo Therapeutics–Trophic Communications: public relations, 202303 service existent by Trophic 2023-03-02
Simulands–SHS Capital: investment, 202303 investment €10m in Simulands by SHS 2023-03-02
BioNTech–Weizmann Institute: mRNA technology, 202303– collab research in Israel with new BioNTech nRNA Excellence Center MOU 2023-03-01
Bico–ABB: laboratory automation equipment, 202302 collab product integration Nucleus Automation Ecosystem + sciFLEXARRAYER of Scienion + ABB Robotics 2023-02-27
VisionHealth–Bruchmann Group: investment, 202302 financing round pre-Series A totalling €3m incl new + lead investor DB Speciality Invest 2023-02-27
VisionHealth–SEVERAL: investment, 202302 financing round pre-Series A €3m led by DB Speciality Invest 2023-02-27
Akttya Therapeutics–CrystalsFirst: drug discovery services, 202302– supply service €na using SmartSoak technology on novel protein targets of Akttyva 2023-02-23
Prosion–Collaborative Drug Discovery: data management software, 202302– supply service Prosion to use CDD Vault to host its RnD data 2023-02-23
Paleo–Planet A: investment, 202302 financing round Series A totalling €12m incl co-lead investor Planet A Ventures 2023-02-22
Paleo–SEVERAL: investment, 202302 financing round Series A €12m led by DSM Venturing + Planet A Ventures 2023-02-22
Resalis Therapeutics–Trophic Communications: public relations, 202302 service existent by Trophic 2023-02-22
Alentis Therapeutics–O Public Relations: public relations, 202302 service existent by O Public Relations 2023-02-17
Lift BioSciences–Resonac: biologics contract manufacturing, 202302– collab developm + manufacturing of N-LIfT for clinical trials by Minaris RM 2023-02-16
Hexagon Bio–Nextech: investment, 202302 financing round Series B totalling $77.3m incl existing investor Nextech 2023-02-13
Hexagon Bio–SEVERAL: investment, 202302 financing round Series B $77.3m from existing + new investors 2023-02-13
Life Science Valley–Lower Saxony (govt): investment, 202302 fund launch with total of €12m incl €6m from NBank 2023-02-13
Life Science Valley–Sartorius: investment, 202302 fund launch with total of €12m incl €6m from Sartorius + Univ Medical Center Göttingen combined 2023-02-13
Life Science Valley–SEVERAL: investment, 202302 fund launch with €12m incl €6m from Niedersachsen + remainder from Sartorius + Univ Göttingen 2023-02-13
Life Science Valley–Univ Göttingen: investment, 202302 fund launch with total of €12m incl €6m from Univ Medical Center Göttingen + Sartorius combined 2023-02-13
Freeline Therapeutics–Ascend GCTx: investment, 202302 acquisition of Freeline Therapeutics GmbH for $25m by Ascend GCTx Ltd 2023-02-10
AMSilk–BRAIN Biotech: biomaterials, 202302– strategic collaboration development of high-performance bio-based protein fibers 2023-02-08
APK–SEVERAL: investment, 202302– financing round €130m incl minority investments from LyondellBasell + KIRKBI A/S 2023-02-08
BrainRepair–OTHER: investment, 202302 investment €50m for 20% of shares of BrainRepair UG by London-based group 2023-02-08
next pagenext page 1 2 3 ... 5 6 7 ... 33 34 35  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top